Daniel W Coyne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2292103/publications.pdf

Version: 2024-02-01

65 papers	3,107 citations	257450 24 h-index	155660 55 g-index
68 all docs	68 docs citations	68 times ranked	2630 citing authors

#	Article	IF	Citations
1	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet, The, 2010, 376, 1543-1551.	13.7	613
2	Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation. Journal of the American Society of Nephrology: JASN, 2007, 18, 975-984.	6.1	362
3	Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD. American Journal of Kidney Diseases, 2006, 47, 263-276.	1.9	198
4	Increased Plasma Leptin Concentration in End-Stage Renal Disease1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 847-850.	3.6	190
5	Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 386-393.	4.5	162
6	Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin. Journal of the American Society of Nephrology: JASN, 2008, 19, 372-379.	6.1	150
7	Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney International, 2003, 63, 217-224.	5.2	93
8	Influence of Industry on Renal Guideline Development. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 3-7.	4.5	81
9	The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney International, 2012, 82, 235-241.	5.2	81
10	Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney International, 2011, 80, 240-244.	5.2	78
11	Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1238-1247.	6.1	75
12	Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease. Expert Opinion on Pharmacotherapy, 2009, 10, 2563-2568.	1.8	74
13	Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. American Journal of Kidney Diseases, 2002, 40, 1283-1288.	1.9	73
14	A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation, 2016, 31, 646-655.	0.7	70
15	Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney International Reports, 2021, 6, 624-635.	0.8	65
16	A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3â€“4 CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1620-1626.	4.5	62
17	Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney International, 2010, 78, 769-773.	5.2	61
18	High-Molecular Weight Iron Dextran. Journal of the American Society of Nephrology: JASN, 2008, 19, 833-834.	6.1	59

#	Article	IF	Citations
19	Hyperleptinemia in Patients with End-Stage Renal Disease Undergoing Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 1998, 18, 34-40.	2.3	54
20	Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney International, 2009, 75, 104-110.	5.2	51
21	New options for the anemia of chronic kidney disease. Kidney International Supplements, 2017, 7, 157-163.	14.2	35
22	Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrology Dialysis Transplantation, 2013, 28, 2260-2268.	0.7	29
23	Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data. Clinical Nephrology, 2017, 88, 59-67.	0.7	29
24	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. Journal of Heart and Lung Transplantation, 2018, 37, 696-705.	0.6	28
25	Phosphate Balance and CKDâ€“Mineral Bone Disease. Kidney International Reports, 2021, 6, 2049-2058.	0.8	22
26	Anemia management in chronic kidney disease: Intravenous iron steps forward. American Journal of Hematology, 2010, 85, 311-312.	4.1	21
27	Sotatercept Safety and Effects onÂHemoglobin, Bone, and Vascular Calcification. Kidney International Reports, 2019, 4, 1585-1597.	0.8	21
28	Paricalcitol and cinacalcet have disparate actionsÂon parathyroid oxyphil cell content inÂpatients with chronic kidney disease. Kidney International, 2017, 92, 1217-1222.	5.2	20
29	Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide. American Journal of Nephrology, 2018, 47, 153-161.	3.1	20
30	How I treat renal anemia. Blood, 2020, 136, 783-789.	1.4	18
31	A Comprehensive Vision for Intravenous Iron Therapy. American Journal of Kidney Diseases, 2008, 52, S14-S20.	1.9	16
32	It's Time to Compare Anemia Management Strategies in Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 740-742.	4.5	16
33	Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era. Kidney Medicine, 2020, 2, 589-599.e1.	2.0	16
34	Practice Recommendations Based on Low, Very Low, and Missing Evidence. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 11-12.	4.5	15
35	Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease. Kidney Research and Clinical Practice, 2013, 32, 11-15.	2.2	15
36	Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3â€“4 chronic kidney disease. Nature Clinical Practice Nephrology, 2008, 4, 364-365.	2.0	14

#	Article	IF	Citations
37	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. Journal of Diabetes and Its Complications, 2018, 32, 1113-1117.	2.3	14
38	Update on intravenous iron choices. Current Opinion in Nephrology and Hypertension, 2014, 23, 186-191.	2.0	10
39	Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study. BMC Nephrology, 2019, 20, 396.	1.8	10
40	Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study. Kidney Medicine, 2020, 2, 307-316.	2.0	9
41	The KDOQI US Commentary on KDIGO Anemia Guideline and Quality of Life. American Journal of Kidney Diseases, 2014, 63, 540.	1.9	8
42	Iron Overload in Dialysis Patients: Rust or Bust?. Kidney International Reports, 2017, 2, 995-997.	0.8	8
43	The Value of Intravenous Iron: Beyond the Cave of Speculation. Journal of the American Society of Nephrology: JASN, 2020, 31, 896-897.	6.1	8
44	Ethical Issues in Dialysisâ€¨Aaron Spital, Series Editor: Managing Anemia in Forâ€Profit Dialysis Chains: When Ethics and Business Conflict. Seminars in Dialysis, 2009, 22, 18-21.	1.3	7
45	Data confusion. Kidney International, 2015, 88, 1445.	5.2	6
46	HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety. American Journal of Nephrology, 2021, 52, 894-898.	3.1	6
47	Mille Verba: Seeking Safe and Efficacious Anemia Management. Seminars in Dialysis, 2009, 22, 590-591.	1.3	5
48	Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. Journal of Nephrology, 2022, 35, 875-888.	2.0	5
49	PIVOTAL trial: iron loading improves clinical outcomes. Nature Reviews Nephrology, 2019, 15, 260-261.	9.6	4
50	Will Targeting Interleukin-6 in the Anemia of CKD Change Our Treatment Paradigm?. Journal of the American Society of Nephrology: JASN, 2021, 32, 6-8.	6.1	4
51	Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease. Kidney Research and Clinical Practice, 2019, 38, 141-144.	2.2	4
52	Groundhog Day: research without old data and old references. Psychological Medicine, 2022, 52, 625-631.	4.5	3
53	Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate. Nephrology Nursing Journal, 2008, 35, 583-7.	0.2	3
54	SP104DECREASES IN WEIGHT WITH BARDOXOLONE METHYL IN OBESE PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. Nephrology Dialysis Transplantation, 2018, 33, i379-i379.	0.7	2

#	Article	IF	Citations
55	Treatment of Iron-Deficiency Anemia with IV Ferumoxytol in CKD Patients: Efficacy Compared with Oral Iron across Different Age Groups.. Blood, 2007, 110, 2679-2679.	1.4	2
56	Introduction to â€œA Road Map for Intravenous Iron and Anemia Management: Preparing for the Futureâ€• American Journal of Kidney Diseases, 2008, 52, S1-S4.	1.9	1
57	The Author Replies. Kidney International Reports, 2018, 3, 218-219.	0.8	1
58	Paricalcitol in the treatment of secondary hyperparathyroidism. Expert Review of Endocrinology and Metabolism, 2006, 1, 159-165.	2.4	0
59	The future of intravenous iron in nephrology. CKJ: Clinical Kidney Journal, 2011, 4, i6-i9.	2.9	0
60	The Author Replies. Kidney International Reports, 2018, 3, 220-222.	0.8	0
61	FP804TWO-YEAR DURABILITY OF IMPROVEMENTS IN EGFR WITH BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: THE LARIAT STUDY. Nephrology Dialysis Transplantation, 2018, 33, i634-i634.	0.7	0
62	Testing Vitamin D Analogues for Vascular Calcification in Patients With CKD. Kidney Medicine, 2020, 2, 385-387.	2.0	0
63	Proactive high-dose IV iron is preferred therapy in ESKD patients: PRO. Kidney360, 2022, 3, 10.34067/KID.0002442021.	2.1	0
64	Comment on â€œDoes ferric gluconate lower epoetin requirements in hemodialysis patients with high ferritin levels?â€• Nature Clinical Practice Nephrology, 2008, 4, E1-E1.	2.0	0
65	Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort. International Journal of Nephrology and Renovascular Disease, 2022, Volume 15, 139-149.	1.8	0